JP2011168588A5 - - Google Patents

Download PDF

Info

Publication number
JP2011168588A5
JP2011168588A5 JP2011026980A JP2011026980A JP2011168588A5 JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5 JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5
Authority
JP
Japan
Prior art keywords
gene
compound
apoptosis inducer
test compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011026980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011168588A (ja
JP5213972B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011026980A priority Critical patent/JP5213972B2/ja
Priority claimed from JP2011026980A external-priority patent/JP5213972B2/ja
Publication of JP2011168588A publication Critical patent/JP2011168588A/ja
Publication of JP2011168588A5 publication Critical patent/JP2011168588A5/ja
Application granted granted Critical
Publication of JP5213972B2 publication Critical patent/JP5213972B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011026980A 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 Expired - Fee Related JP5213972B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004115404 2004-04-09
JP2004115404 2004-04-09
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006512126A Division JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012046652A Division JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Publications (3)

Publication Number Publication Date
JP2011168588A JP2011168588A (ja) 2011-09-01
JP2011168588A5 true JP2011168588A5 (https=) 2012-04-19
JP5213972B2 JP5213972B2 (ja) 2013-06-19

Family

ID=35124844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2011026980A Expired - Fee Related JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Country Status (5)

Country Link
US (3) US8193332B2 (https=)
EP (4) EP2520652B1 (https=)
JP (3) JP4761389B2 (https=)
KR (1) KR101234281B1 (https=)
WO (1) WO2005097189A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625853B1 (en) 2003-05-19 2015-07-08 Genecare Research Institute Co., Ltd Apoptosis inducer for cancer cell
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1816194A4 (en) * 2004-11-19 2009-02-18 Genecare Res Inst Co Ltd CANCER-SPECIFIC PROLIFERATION INHIBITORS
US20090208938A1 (en) * 2005-02-10 2009-08-20 Centre National De La Recherche Scientifique Use of the MCM8 Gene for the Preparation of a Pharmaceutical Composition
EP1915622A2 (en) * 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
WO2008047574A1 (fr) * 2006-09-28 2008-04-24 Genecare Research Institute Co., Ltd. Sensibilisateur pour agent anticancéreux
JP4940412B2 (ja) * 2006-10-16 2012-05-30 財団法人ヒューマンサイエンス振興財団 抗癌性物質のスクリーニング方法
CA2666584A1 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010034487A2 (en) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Means for inhibiting the expression of orc-1
WO2010045526A1 (en) * 2008-10-17 2010-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Geminin inhibitors as tumor treatment
EP2370580B1 (en) * 2008-12-04 2019-09-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
EP2403946A4 (en) * 2009-03-04 2012-11-14 TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
EP2467481A4 (en) * 2009-07-24 2013-01-16 Curna Inc TREATMENT OF SIRTUIN (SIRT) -REVATED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A SIRTUIN (SIRT)
NZ602089A (en) 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
US20130071395A1 (en) * 2010-05-28 2013-03-21 Case Western Reserve University Compositions and methods for treating pathologies
WO2012090479A1 (en) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 as a target gene for cancer therapy and diagnosis
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101623814B1 (ko) 2014-02-21 2016-05-24 두산중공업 주식회사 수냉각 발전기의 분리형 냉각수 순환 구조 및 그에 따른 냉각 방법
JP2015167527A (ja) * 2014-03-07 2015-09-28 学校法人東京理科大学 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体
EP3237444B1 (en) * 2014-12-23 2020-05-06 Centre National De La Recherche Scientifique Use of rad18 inhibitors in the treatment of tumors
CN104673801B (zh) * 2015-02-12 2018-09-11 中山大学附属第三医院 一种肝癌基因ndc80及其应用
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
AU2017327384B2 (en) * 2016-09-13 2021-05-20 The Jackson Laboratory Targeted enhanced DNA demethylation
EP3533869B1 (en) * 2016-10-26 2025-08-20 Denka Company Limited Mutant human dna polymerase
US20200121703A1 (en) * 2017-06-26 2020-04-23 The Cleveland Clinic Foundation Cancer treatment
WO2020055187A1 (ko) * 2018-09-12 2020-03-19 기초과학연구원 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법
JP2022020872A (ja) * 2020-06-01 2022-02-02 均 石井 抗がん剤。

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3386597A (en) * 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
GB0004193D0 (en) * 2000-02-22 2000-04-12 Isis Innovation A genetic determinant for malignant melanoma
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7241743B2 (en) 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
WO2003046207A2 (en) 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
AU2003250831A1 (en) * 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
US8252520B2 (en) * 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1625853B1 (en) 2003-05-19 2015-07-08 Genecare Research Institute Co., Ltd Apoptosis inducer for cancer cell
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1816194A4 (en) 2004-11-19 2009-02-18 Genecare Res Inst Co Ltd CANCER-SPECIFIC PROLIFERATION INHIBITORS

Similar Documents

Publication Publication Date Title
JP2011168588A5 (https=)
Zhang et al. Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR‐138 targets TERT and PD‐L1
JP2011037847A5 (https=)
Li et al. Long non‐coding RNA FOXP 4‐AS 1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer
Yu et al. Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells
Shibata et al. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels
Neudecker et al. Emerging roles for microRNAs in perioperative medicine
Alegre et al. Circulating biomarkers in malignant melanoma
Skommer et al. Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death
Wang et al. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis
Wang et al. The role of microRNA in cisplatin resistance or sensitivity
Xue et al. MicroRNA-targeted therapeutics for lung cancer treatment
Wang et al. miR-197: A novel biomarker for cancers
Wang et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9
JP2011162558A5 (https=)
HK1200837A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
JP2012050449A5 (https=)
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NO20092965L (no) Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner
WO2012102527A3 (ko) 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
Tong et al. Retracted: Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR‐155‐5p
WO2014162008A3 (en) Biomarker signatures for predicting drug response in hodkin's lymphoma
JP2014221834A5 (https=)
Ding et al. HCV infection induces the upregulation of miR-221 in NF-κB dependent manner
JP2016528914A5 (https=)